In silico approaches to predicting cancer potency for risk assessment of genotoxic impurities in drug substances

被引:25
作者
Bercu, Joel P. [1 ]
Morton, Stuart M. [1 ]
Deahl, J. Thom [1 ]
Gombar, Vijay K. [1 ]
Callis, Courtney M. [1 ]
van Lier, Robert B. L. [1 ]
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
关键词
Genotoxic; Impurities; In silico; Carcinogenicity; Threshold of toxicological concern; Pharmaceutical; TD50; Cancer potency; AUTOMATED STRUCTURE EVALUATION; NATIONAL-TOXICOLOGY-PROGRAM; CARCINOGENIC-POTENCY; GENERAL LITERATURE; CHEMICAL CARCINOGENESIS; DATABASE CPDB; CONCERN TTC; PHARMACEUTICALS; THRESHOLD; SAFETY;
D O I
10.1016/j.yrtph.2010.03.010
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
The current risk assessment approach for addressing the safety of very small concentrations of genotoxic impurities (GTIs) in drug substances is the threshold of toxicological concern (TIC). The TTC is based on several conservative assumptions because of the uncertainty associated with denying an excess cancer risk when no carcinogenicity data are available for the impurity. It is a default approach derived from a distribution of carcinogens and does not take into account the properties of a specific chemical. The purpose of the study was to use in silico tools to predict the cancer potency (TD50) of a compound based on its structure. Structure activity relationship (SAR) models (classification/regression) were developed from the carcinogenicity potency database using MultiCASE and VISDOM. The MultiCASE classification models allowed the prediction of carcinogenic potency class, while the VISDOM regression models predicted a numerical TD50. A step-wise approach is proposed to calculate predicted numerical TD50 values for compounds categorized as not potent. This approach for non-potent compounds can be used to establish safe levels greater than the TTC for GTIs in a drug substance. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:300 / 306
页数:7
相关论文
共 46 条
[1]  
[Anonymous], 2005, GUIDELINES CARCINOGE
[2]   Risk assessment of substances that are both genotoxic and carcinogenic -: Report of an International Conference organized by EFSA and WHO with support of ILSI Europe [J].
Barlow, S. ;
Renwick, A. G. ;
Kleiner, J. ;
Bridges, J. W. ;
Busk, L. ;
Dybing, E. ;
Edler, L. ;
Eisenbrand, G. ;
Fink-Gremmels, J. ;
Knaap, A. ;
Kroes, R. ;
Liem, D. ;
Mueller, D. J. G. ;
Page, S. ;
Rolland, V. ;
Schlatter, J. ;
Tritscher, A. ;
Tueting, W. ;
Wurtzen, G. .
FOOD AND CHEMICAL TOXICOLOGY, 2006, 44 (10) :1636-1650
[3]  
Benfenati E., 2009, PREDICTIVE MODELS CA, V27, P57
[4]   Toxicological and clinical computational analysis and the USFDA/CDER [J].
Benz, R. Daniel .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2007, 3 (01) :109-124
[5]   Application of the threshold of toxicological concern approach to ingredients in personal and household care products [J].
Blackburn, K ;
Stickney, JA ;
Carlson-Lynch, HL ;
McGinnis, PM ;
Chappell, L ;
Felter, SP .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2005, 43 (03) :249-259
[6]  
*COMM MED PROD HUM, 2007, EMEACHMPQWP251344200
[7]  
*COMM MED PROD HUM, 2008, EMEACHMPSWP431994200
[8]   An impact analysis of the application of the threshold of toxicological concern concept to pharmaceuticals [J].
Delaney, Edward J. .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2007, 49 (02) :107-124
[9]   The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development [J].
Dobo, KL ;
Greene, N ;
Cyr, MO ;
Caron, S ;
Ku, WW .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2006, 44 (03) :282-293
[10]   UNCERTAINTY IN CANCER RISK ESTIMATES [J].
GAYLOR, DW ;
CHEN, JJ ;
SHEEHAN, DM .
RISK ANALYSIS, 1993, 13 (02) :149-154